155
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives

, , &
Pages 4016-4024 | Received 15 Jul 2019, Accepted 03 Sep 2019, Published online: 23 Sep 2019

References

  • Aldinucci, M., Bagnasco, S., Lusso, S., Pasteris, P., Rabellino, S., & Vallero, S. (2017). OCCAM: A flexible, multi-purpose and extendable HPC cluster. Journal of Physics: Conference Series, 898, 082039. doi:10.1088/1742-6596/898/8/082039
  • Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., … Yu, W. (2000). Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry, 43(15), 2797–2804. doi:10.1021/jm990628o
  • Barducci, A., Bussi, G., & Parrinello, M. (2008). Well-tempered metadynamics: a smoothly converging and tunable free-energy method. Physical Review Letters, 100(2), 020603-1. doi:10.1103/PhysRevLett.100.020603
  • Boschi, D., Tosco, P., Chandra, N., Chaurasia, S., Fruttero, R., Griffin, R. J., … Gasco, A. (2013). 6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity. European Journal of Medicinal Chemistry, 68, 333–338. doi:10.1016/j.ejmech.2013.07.031
  • Cortese, D., Chegaev, K., Guglielmo, S., Wang, L., Golding, B. T., Cano, C., & Fruttero, R. (2016). Synthesis and biological evaluation of N2‐substituted 2,4‐diamino‐6‐cyclohexylmethoxy‐5‐nitrosopyrimidines and related 5‐cyano‐NNO‐azoxy derivatives as cyclin‐dependent kinase 2 (CDK2) inhibitors. ChemMedChem, 11(16), 1705–1708. doi:10.1002/cmdc.201600108
  • Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J. A., … Whitfield, H. J. (2002). Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology, 9, 745–749. doi:10.1038/nsb842
  • Hardcastle, I. R., Arris, C. E., Bentley, J., Boyle, F. T., Chen, Y., Curtin, N. J., … Whitfield, H. J. (2004). N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. Journal of Medicinal Chemistry, 47(15), 3710–3722. doi:10.1021/jm0311442
  • Homeyer, N., & Gohlke, H. (2012). Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Molecular Informatics, 31(2), 114–122. doi:10.1002/minf.201100135
  • Kong, X., Sun, H., Pan, P., Tian, S., Li, D., Li, Y., & Hou, T. (2016). Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. Physical Chemistry Chemical Physics, 18(3), 2034–2046. doi:10.1039/C5CP05622E
  • Malumbres, M., Pevarello, P., Barbacid, M., & Bischoff, J. R. (2008). CDK inhibitors in cancer therapy: What is next? Trends in Pharmacological Sciences, 29(1), 16–21. doi:10.1016/j.tips.2007.10.012
  • Patel, J. S., Berteotti, A., Ronsisvalle, S., Rocchia, W., & Cavalli, A. (2014). Steered molecular dynamics simulations for studying protein-ligand interaction in cyclin-dependent kinase 5. Journal of Chemical Information and Modeling, 54(2), 470–480. doi:10.1021/ci4003574
  • Seeber, M., Felline, A., Raimondi, F., Muff, S., Friedman, R., Rao, F., … Fanelli, F. (2011). Wordom: a user-friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. Journal of Computational Chemistry, 32(6), 1183–1194. doi:10.1002/jcc.21688
  • Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019). Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. Journal of Medicinal Chemistry, 62(9), 4233–4251. doi:10.1021/acs.jmedchem.8b01469
  • Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017). Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacology & Therapeutics, 173, 83–105. doi:10.1016/j.pharmthera.2017.02.008

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.